Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement - PubMed (original) (raw)

Review

Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement

A Kinter et al. Immunol Res. 1996.

Abstract

A hallmark of human immunodeficiency virus (HIV) infection is the progressive loss of CD4+ T lymphocytes; however, qualitative defects in immune responses occur prior to the precipitous drop CD4+ T cell numbers. One of the first immunologic defects to be described in HIV-infected individuals is a deficiency in interleukin (IL)-2 production. The addition of IL-2 in vitro to cultures of mononuclear cells from HIV-infected individuals partially or completely restored certain defective cellular immune responses. However, production of or addition of IL-2 has also been associated with increased viral replication in infected T cells. These observations underscore the pernicious correlation between immune activation and HIV replication. However, recent in vitro and in vivo studies have provided promising preliminary results suggesting that, at least at certain stages of disease, the benefits of IL-2 mediated immune enhancement may outweigh or override the inductive effects of this cytokine on HIV production.

PubMed Disclaimer

Similar articles

• Interleukin 2 induces CD8+ T cell-mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression.
  Kinter AL, Bende SM, Hardy EC, Jackson R, Fauci AS. Kinter AL, et al. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10985-9. doi: 10.1073/pnas.92.24.10985. Proc Natl Acad Sci U S A. 1995. PMID: 7479922 Free PMC article.
• Methods of using interleukin 2 to enhance HIV-specific immune responses.
  Xu J, Whitman L, Lori F, Lisziewicz J. Xu J, et al. AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):289-93. doi: 10.1089/088922202753472865. AIDS Res Hum Retroviruses. 2002. PMID: 11860676
• Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15.
  Seder RA, Grabstein KH, Berzofsky JA, McDyer JF. Seder RA, et al. J Exp Med. 1995 Oct 1;182(4):1067-77. doi: 10.1084/jem.182.4.1067. J Exp Med. 1995. PMID: 7561680 Free PMC article.
• Experiences in immune reconstitution. The rationale for interleukin-2 administration to HIV-infected individuals.
  Ghezzi S, Vicenzi E, Soldini L, Tambussi G, Murone M, Lazzarin A, Poli G. Ghezzi S, et al. J Biol Regul Homeost Agents. 1997 Jan-Jun;11(1-2):74-8. J Biol Regul Homeost Agents. 1997. PMID: 9418168 Review.

Cited by

• Host factors influencing susceptibility to HIV infection and AIDS progression.
  Lama J, Planelles V. Lama J, et al. Retrovirology. 2007 Jul 25;4:52. doi: 10.1186/1742-4690-4-52. Retrovirology. 2007. PMID: 17651505 Free PMC article. Review.
• Differential expression of perforin in cytotoxic lymphocyte in HIV/AIDS patients of China.
  Qi W, Yongjun J, Yanan W, Zining Z, Xiaoxu H, Jing L, Hong S. Qi W, et al. J Clin Immunol. 2006 Jul;26(4):339-46. doi: 10.1007/s10875-006-9027-1. Epub 2006 Jun 13. J Clin Immunol. 2006. PMID: 16770700
• Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone.
  Goodier MR, Imami N, Moyle G, Gazzard B, Gotch F. Goodier MR, et al. Clin Exp Immunol. 2003 Dec;134(3):470-6. doi: 10.1111/j.1365-2249.2003.02329.x. Clin Exp Immunol. 2003. PMID: 14632753 Free PMC article.
• Management of HIV-infected Patients with Multidrug-resistant Virus.
  Montaner JS, Harris M. Montaner JS, et al. Curr Infect Dis Rep. 2002 Jun;4(3):259-265. doi: 10.1007/s11908-002-0089-9. Curr Infect Dis Rep. 2002. PMID: 12015920
• T cell signaling mechanisms that regulate HIV-1 infection.
  Unutmaz D. Unutmaz D. Immunol Res. 2001;23(2-3):167-77. doi: 10.1385/IR:23:2-3:167. Immunol Res. 2001. PMID: 11444382

References

1. 1. J Immunol. 1989 Jun 15;142(12):4248-55 - PubMed
2. 1. N Engl J Med. 1995 Mar 2;332(9):567-75 - PubMed
3. 1. J Clin Invest. 1989 Dec;84(6):1892-9 - PubMed
4. 1. J Biol Response Mod. 1984 Oct;3(5):512-6 - PubMed
5. 1. J Acquir Immune Defic Syndr. 1992 Dec;5(12):1181-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program